Delivery Order SPE2DB20D2104-SPE2DB25FNBUG
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Brilinta 90 mg tablets (60-count) with a ceiling value of $1,514.37. The contract, awarded on September 5, 2025, with an ultimate completion date of September 8, 2025, utilizes firm fixed pricing under a non-set-aside, competitively awarded delivery order. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance for this pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Brilinta 90 mg tablets (60-count) valued at $2,535.30, with an ultimate completion date of September 26, 2025. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order for pharmaceutical supply. The contract was fulfilled by AmerisourceBergen's Corporate Office division, with performance taking place at the company's headquarters in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 60 tablets of Brilinta 90 mg, a cardiovascular medication, under a firm fixed-price contract valued at $2,691.67. The order, issued on August 21, 2025, with completion targeted for August 22, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this delivery order from its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Brilinta 60 mg tablets (60-count units) with a ceiling value of $4,769.52. This firm fixed price delivery order, with an ultimate completion date of July 21, 2025, represents a competitively awarded, non-set-aside contract utilizing AmerisourceBergen's existing pharmaceutical supply agreement. The order will be fulfilled from the company's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Brilinta 90 mg tablets (60-count) under a firm fixed-price contract valued at $4,405.19, with an ultimate completion date of August 7, 2025. This non-set-aside delivery order was competitively awarded and represents a continuation of AmerisourceBergen's pharmaceutical supply services to the federal government. The place of performance is listed as the vendor's corporate office in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Brilinta 60 mg tablets (60-count) with a ceiling value of $1,116.90. This non-set-aside, competitively awarded contract is structured as a delivery order under a firm fixed-price arrangement, with an ultimate completion date of September 24, 2025. The award was issued on September 23, 2025, and the place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 60 tablets of Brilinta 90 mg, a pharmaceutical product used in cardiovascular treatment, under a firm fixed-price contract valued at $1,266.36. The award was issued on July 31, 2025, with an ultimate completion date of August 1, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $1,926.42 to AmerisourceBergen Drug Corp for the supply of Brilinta 90 mg tablets (quantity 60s) on August 26, 2025, with completion scheduled for August 27, 2025. This firm fixed price delivery order represents a non-set-aside award executed through open competition. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, supporting the federal government's pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $32,625.18 to AmerisourceBergen Drug Corp for the supply of Brilinta 90 mg tablets (60-count packages) on September 23, 2025, with an ultimate completion date of September 24, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Brilinta is an antiplatelet medication commonly used in...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,385.68 for 60 mg tablets of Brilinta (ticagrelor), an antiplatelet medication, with an ultimate completion date of September 15, 2025. This is a firm fixed price delivery order issued under a non-competitive set-aside arrangement. The contract is being performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FNBUGDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 60 mg tablets of Brilinta, a cardiovascular medication, with a ceiling value of $2,468.16. This non-set-aside, competitively awarded contract was issued on September 26, 2025, with an ultimate completion date of September 29, 2025. The firm fixed price delivery order will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026. This prime contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, including the Defense Health Agency and U.S. Coast Guard. AmerisourceBergen's status as a major pharmaceutical distributor and critical federal medical procurement vendor is reflected in its ability to fulfill varied pharmaceutical needs through open competition across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 9/26/25 |